Latest Insider Transactions at Biocryst Pharmaceuticals Inc (BCRX)
This section provides a real-time view of insider transactions for Biocryst Pharmaceuticals Inc (BCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOCRYST PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOCRYST PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2023
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
12,866
-13.59%
|
$102,928
$8.04 P/Share
|
|
Jun 13
2023
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
25,000
-2.4%
|
-
|
|
Jun 13
2023
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+36.12%
|
-
|
|
Jun 13
2023
|
Kenneth B Lee Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+19.56%
|
-
|
|
Jun 13
2023
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+31.1%
|
-
|
|
Jun 13
2023
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+25.37%
|
-
|
|
Jun 13
2023
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+36.12%
|
-
|
|
Jun 13
2023
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+20.91%
|
-
|
|
Jun 13
2023
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+25.43%
|
-
|
|
Jun 13
2023
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+36.12%
|
-
|
|
Jun 13
2023
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+15.03%
|
-
|
|
Jun 13
2023
|
George B Abercrombie Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,745
+36.12%
|
-
|
|
May 31
2023
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,360
+6.27%
|
$10,880
$8.27 P/Share
|
|
May 31
2023
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
680
+2.05%
|
$5,440
$8.27 P/Share
|
|
May 31
2023
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
680
+2.06%
|
$5,440
$8.27 P/Share
|
|
Apr 03
2023
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,000
-3.27%
|
$56,000
$8.29 P/Share
|
|
Mar 21
2023
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,055
+2.9%
|
$93,165
$3.22 P/Share
|
|
Feb 28
2023
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,259
+2.2%
|
$18,072
$8.85 P/Share
|
|
Feb 28
2023
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
635
+1.96%
|
$5,080
$8.85 P/Share
|
|
Feb 28
2023
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,271
+6.27%
|
$10,168
$8.85 P/Share
|
|
Feb 28
2023
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
635
+1.96%
|
$5,080
$8.85 P/Share
|
|
Feb 01
2023
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
100,000
-9.02%
|
$1,000,000
$10.38 P/Share
|
|
Feb 01
2023
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+8.27%
|
$500,000
$5.45 P/Share
|
|
Jan 31
2023
|
Kenneth B Lee Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+22.35%
|
$15,000
$1.71 P/Share
|
|
Dec 29
2022
|
Jon P Stonehouse President & CEO |
BUY
Bona fide gift
|
Indirect |
10,000
+33.33%
|
-
|
|
Dec 29
2022
|
Jon P Stonehouse President & CEO |
SELL
Bona fide gift
|
Direct |
10,000
-0.98%
|
-
|
|
Dec 19
2022
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+14.66%
|
-
|
|
Dec 19
2022
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.16%
|
-
|
|
Dec 19
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+26.16%
|
-
|
|
Dec 19
2022
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
127,500
+11.16%
|
-
|
|
Dec 19
2022
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+27.43%
|
-
|
|
Dec 19
2022
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+12.75%
|
-
|
|
Dec 15
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
14,100
-1.56%
|
$141,000
$10.9 P/Share
|
|
Dec 15
2022
|
Alane P Barnes Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,175
-2.06%
|
$41,750
$10.88 P/Share
|
|
Dec 15
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
445
-3.97%
|
$4,450
$10.9 P/Share
|
|
Dec 15
2022
|
Charles K Gayer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,100
-2.8%
|
$61,000
$10.9 P/Share
|
|
Dec 15
2022
|
Anthony Doyle Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,700
-3.36%
|
$57,000
$10.9 P/Share
|
|
Dec 15
2022
|
Helen M. Thackray Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
3,125
-2.29%
|
$31,250
$10.89 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
82,656
-8.4%
|
$991,872
$12.8 P/Share
|
|
Dec 02
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
82,656
+7.75%
|
$82,656
$1.42 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
SELL
Open market or private sale
|
Direct |
214,917
-19.24%
|
$2,793,921
$13.0 P/Share
|
|
Dec 01
2022
|
Jon P Stonehouse President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
214,917
+16.14%
|
$214,917
$1.42 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
SELL
Open market or private sale
|
Direct |
8,600
-43.44%
|
$111,800
$13.01 P/Share
|
|
Dec 01
2022
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,600
+30.28%
|
$8,600
$1.42 P/Share
|
|
Nov 30
2022
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.34%
|
$5,473
$13.36 P/Share
|
|
Nov 30
2022
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,497
+1.51%
|
$19,461
$13.36 P/Share
|
|
Nov 30
2022
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
842
+4.54%
|
$10,946
$13.36 P/Share
|
|
Nov 30
2022
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
421
+1.33%
|
$5,473
$13.36 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
31,515
-9.55%
|
$409,695
$13.88 P/Share
|
|
Nov 14
2022
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+14.15%
|
$100,000
$1.42 P/Share
|